You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel QcrB Inhibitors for the Treatment of Tuberculosis
SBC: LGENIA INC. Topic: NIAIDAbstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds, will die due to AMR associated with TB. Long treatment times and increasing resistance to TB drugs ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
High Density Cell Respirator (HDCR) for the production of vectors, viruses and vaccines
SBC: XDemics Corporation Topic: NCATSPROJECT SUMMARY/ABSTRACT This Phase I/II STTR Fast Track proposal responds to the call from the 2018/2019 NCATS SBIR/STTR Research Priorities to develop technologies so that “new treatments and cures for disease can be delivered to patients more quickly”. The production of life-altering gene editing vectors, cancer killing viruses, and life- saving vaccines currently depends on traditional cel ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Pharmacological chaperones for the treatment of Open-Angle Glaucoma
SBC: Viewpoint Therapeutics, Inc. Topic: NEIOpen-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Genes-to-Molecules Platform for Expanding Natural Product Diversity
SBC: Lassogen, Inc. Topic: NCCIHProject Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community
SBC: EPERTURE LLC Topic: NIAProject Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension
SBC: Technology Commercialization Partners LLC Topic: NHLBIABSTRACT Pulmonary hypertension (PH) is a highly debilitating disease that affects about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. The life expectancy for these patients is less than 10 years after diagnosis, and no specific drugs are available for pharmacologic treatment. Despite the introduction PDE5, prostacyclin analogs, and endothelin antag ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Detection of perfuorooctanoic acid (PFOA) and perfluorooctane sulfonate(PFOS) in liquid samples.
SBC: SEACOAST SCIENCE, INC. Topic: NIEHSPerfluoroalkyl substances (PFAS) such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate) are toxic and persistent compounds resulting from the production and use of fluoropolymers such as Gortex® and Teflon ®. The structure of PFAS preclude environmental degradation and can lead to bioaccumulation in animals and humans. Reported adverse effects of these compounds in humans include: ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Recombinant Fc fusions for treatment of uropathogenic E. coli
SBC: Planet Biotechnology Incorporated Topic: 300Urinary tract infections (UTIs) are among the most common bacterial infections, affecting 150 million people worldwide each year. In the USA, community-acquired UTIs account for about 11 million cases each year that cost the U.S. public health budget $5 billion annually. Uropathogenic Escherichia coli (UPEC) accounts for up to 80% of UTIs. While UTIs are currently treated with antibiotics, the fre ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A novel role for Reelin therapeutics in inflammatory bowel disease
SBC: REELIN THERAPEUTICS, INC. Topic: 300Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemia
SBC: BRIDGENE BIOSCIENCES INC Topic: 102PROJECT SUMMARY Acute myeloid leukemia (AML), a malignant disease of hematopoietic precursor cells in the bone marrow, is one of the most common cancers in adults accounting for 1% of all cancers. AML is typically diagnosed later in life with individuals 60 and older having a long-term survival rate of merely 5-15%. Cytogenic analysis of the abnormal cells at the time of diagnosis has proven to be ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health